Filing Flows › Puma Biotechnology (PBYI) › Recalls, complaints & regulation
Puma Biotechnology (PBYI): clinical trials
Puma Biotechnology (PBYI) beyond its filings: 3 active clinical trials.
Puma Biotechnology's latest quarter
Puma Biotechnology, Q3 2026: revenue $55.1M (+1% year over year), operating margin 9.6%, net earnings $6.0M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Puma Biotechnology have?
3 active studies on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.